362 related articles for article (PubMed ID: 20829826)
1. Biopharmaceutical benchmarks 2010.
Walsh G
Nat Biotechnol; 2010 Sep; 28(9):917-24. PubMed ID: 20829826
[No Abstract] [Full Text] [Related]
2. Biopharmaceutical benchmarks--2003.
Walsh G
Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
[No Abstract] [Full Text] [Related]
3. Use of benchmarking in the development of biopharmaceutical products.
Giffin M; McLeish S
Biotechnol Annu Rev; 2003; 9():279-84. PubMed ID: 14650932
[TBL] [Abstract][Full Text] [Related]
4. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
5. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
[TBL] [Abstract][Full Text] [Related]
6. Congress works to permit 'biosimilar' drugs very soon.
Carroll J
Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
[No Abstract] [Full Text] [Related]
7. Follow-on biologics: competition in the biopharmaceutical marketplace.
Devine JW; Cline RR; Farley JF
J Am Pharm Assoc (2003); 2006; 46(2):193-201; quiz 202-4. PubMed ID: 16602229
[TBL] [Abstract][Full Text] [Related]
8. Biopharmaceutical benchmarks 2006.
Walsh G
Nat Biotechnol; 2006 Jul; 24(7):769-76. PubMed ID: 16841057
[TBL] [Abstract][Full Text] [Related]
9. Data exclusivity for biologics.
Grabowski H; Long G; Mortimer R
Nat Rev Drug Discov; 2011 Jan; 10(1):15-6. PubMed ID: 21193860
[No Abstract] [Full Text] [Related]
10. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1.
Kuhrt K; Chace-Ortiz M
IDrugs; 2009 Dec; 12(12):760-4. PubMed ID: 19943217
[TBL] [Abstract][Full Text] [Related]
11. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
12. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
13. Quality assurance and quality control for biopharmaceutical products.
Geigert J
Pharm Biotechnol; 2002; 14():361-404. PubMed ID: 12189728
[No Abstract] [Full Text] [Related]
14. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
15. Fresh from the biologic pipeline-2009.
Sheridan C
Nat Biotechnol; 2010 Apr; 28(4):307-10. PubMed ID: 20379168
[No Abstract] [Full Text] [Related]
16. Generic Pharmaceutical Association (GPhA)--2009 annual meeting. 23-25 February 2009, Naples, FL, USA.
Kennedy B
IDrugs; 2009 Apr; 12(4):227-9. PubMed ID: 19350465
[No Abstract] [Full Text] [Related]
17. Development of specifications for biotechnology products--perspective from Europe.
Trouvin JH
Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
[No Abstract] [Full Text] [Related]
18. Regulation of biogenerics: a survey of viewpoints.
Nieminen O; Nordström K
BioDrugs; 2004; 18(6):399-406. PubMed ID: 15571423
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: policy, clinical, and regulatory considerations.
Gottlieb S
Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
[TBL] [Abstract][Full Text] [Related]
20. Mammalian cell cultures for biologics manufacturing.
Kantardjieff A; Zhou W
Adv Biochem Eng Biotechnol; 2014; 139():1-9. PubMed ID: 24258145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
